

## Programme

### FRIDAY 11TH SEPTEMBER 2020

#### OPENING SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:00 – 15:15 hours

EDT (UTC-4 New York, Montreal, Lima) 7:00 AM – 9:15 AM

CST (UTC+8 Beijing, Manila, Perth) 19:00 – 21:15 hours

	<b>Opening</b>	<i>Andrea Doria (Italy)</i> <i>Ronald van Vollenhoven (Netherlands)</i>
	Keynote	
	<i>Moderator: Andrea Doria (Italy)</i>	
	Understanding and treating SLE: A new era is dawning	<i>Ronald van Vollenhoven (Netherlands)</i>
<b>Debate: New Developments in Basic Science and Clinical Research: Defining SLE</b>		
	<i>Moderator: Ricard Cervera (Spain)</i>	
	The matter of the debate	<i>Ricard Cervera (Spain)</i>
	A majority of lupus patients (will) need a biologic!	<i>David Isenberg (UK)</i>
	A minority of lupus patients (will) need a biologic!	<i>Murray Urowitz (Canada)</i>

#### PLENARY I: NEW ASPECTS IN THE MANAGEMENT OF SLE

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30 – 17:00 hours

EDT (UTC-4 New York, Montreal, Lima) 9:30 AM – 11:00 AM

CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:00 hours

	<i>Moderators: Zahir Amoura (France), Bernardo Pons-Estel (Argentina)</i>	
	Measuring SLE disease activity in 2020: Perspectives from clinical research	<i>Luís Inês (Portugal)</i>
	Lifestyle for lupus patients: exercise, diet, and well-being: Perspectives from clinical practice	<i>Chiara Tani (Italy)</i>
	Microangiopathy in SLE: A diagnostic and therapeutic challenge	<i>Ricard Cervera (Spain)</i>
	<i>Panel Discussion and Q&amp;A</i>	<i>All</i>

#### PLENARY II: NOVEL THERAPEUTIC DEVELOPMENTS IN 2020

CET (UTC+2 Paris, Amsterdam, Berlin) 17:30 – 19:30 hours

EDT (UTC-4 New York, Montreal, Lima) 11:30 AM – 1:30 PM

CST (UTC+8 Beijing, Manila, Perth) 23:30 – 01:30 hours

	<i>Moderators: Richard Furie (USA), Ronald van Vollenhoven (Netherlands)</i>	
	Plasma-cell directed therapies	<i>Reinhard Voll (Germany)</i>
	IL-12/23 directed therapies	<i>Bevra Hahn (USA)</i>
	Novel intracellular pathways	<i>Thomas Dörner (Germany)</i>
	Molecules in early development	<i>Richard Furie (USA)</i>
	<i>Panel Discussion and Q&amp;A</i>	<i>All</i>

### SATURDAY 12TH SEPTEMBER 2020

#### PLENARY II: NOVEL THERAPEUTIC DEVELOPMENTS IN 2020

##### (Recorded Session from Friday. Live Panel Discussion and Q&A)

CET (UTC+2 Paris, Amsterdam, Berlin) 07:30 – 09:30 hours

EDT (UTC-4 New York, Montreal, Lima) 1:30 AM – 3:30 AM

CST (UTC+8 Beijing, Manila, Perth) 13:30 – 15:30 hours

	<i>Moderators: Richard Furie (USA), Ronald van Vollenhoven (Netherlands)</i>	
	Plasma-cell directed therapies	<i>Reinhard Voll (Germany)</i>
	IL-12/23 directed therapies	<i>Bevra Hahn (USA)</i>
	Novel intracellular pathways	<i>Thomas Dörner (Germany)</i>
	Molecules in early development stage	<i>Richard Furie (USA)</i>
	<i>Panel Discussion and Q&amp;A</i>	<i>All</i>

**FOUR HOT TOPICS (SESSION 1)**

CET (UTC+2 Paris, Amsterdam, Berlin) 10:00 – 11:50 hours

EDT (UTC-4 New York, Montreal, Lima) 4.00 AM – 5.50 AM

CST (UTC+8 Beijing, Manila, Perth) 16:00 – 17:50 hours

	<i>Moderator: Thomas Dörner (Germany)</i>	
	Remission and low disease activity: the new targets for treatment	<i>George Bertias (Greece)</i>
	Belimumab helps lupus patients to achieve lupus targets	<i>Andrea Doria (Italy)</i>
	Can we withdraw low-dose prednisone in remitted patients?	<i>Zahir Amoura (France)</i>
	Can we withdraw immunosuppressants in remitted patients?	<i>Margherita Zen (Italy)</i>
	<i>Panel Discussion and Q&amp;A</i>	
	<i>All</i>	

**CASE STUDY INTERACTIVE WORKSHOPS (SESSION 1)**

CET (UTC+2 Paris, Amsterdam, Berlin) 12:00 – 13:30 hours

EDT (UTC-4 New York, Montreal, Lima) 6:00 AM – 7:30 AM

CST (UTC+8 Beijing, Manila, Perth) 18:00 – 19:30 hours

	<i>Moderator/Facilitator: Andrea Doria (Italy)</i>	
	Management of refractory skin lupus	<i>Annegret Kuhn (Germany), Marzia Caproni (Italy)</i>
	<i>Moderator/Facilitator: Bernardo Pons-Estel (Argentina)</i>	
	Management of cardiovascular risk in SLE	<i>Murray Urowitz (Canada), Eloisa Bonfá (Brazil)</i>
	<i>Moderator/Facilitator: Sandra Navarra (Philippines)</i>	
	Fertility and pregnancy issues in patients with lupus nephritis	<i>Angela Tincani (Italy), Liz Lightstone (UK)</i>
	<i>Moderator/Facilitator: David Isenberg (UK)</i>	
	Rare disease manifestations in SLE	<i>Zahir Amoura (France), Richard Furie (USA)</i>

**PRIME TIME SESSION**

CET (UTC+2 Paris, Amsterdam, Berlin) 13:30 – 15:00 hours

EDT (UTC-4 New York, Montreal, Lima) 7:30 AM – 9:00 AM

CST (UTC+8 Beijing, Manila, Perth) 19.30 – 21:00 hours

	<b>Hot Topic</b>	
	<i>Moderators: Murray Urowitz (Canada), David Isenberg (UK)</i>	
	Optimal assessment and monitoring of SLE patients in clinical practice	<i>Alexandre Voskuyl (Netherlands)</i>
	<b>State-of-the-art</b>	
	<i>Moderators: Bevra Hahn (USA), Sandra Navarra (Philippines)</i>	
	Diagnosis and treatment of neuropsychiatric lupus	<i>Marcello Govoni (Italy)</i>
	Covid-19 and SLE – What do we know today?	<i>Fabrizio Conti (Italy)</i>

**CASE STUDY INTERACTIVE WORKSHOPS (SESSION 2)**

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30 – 17:00 hours

EDT (UTC-4 New York, Montreal, Lima) 9:30 AM – 11:00 AM

CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:00 hours

	<i>Moderator/Facilitator: Andrea Doria (Italy)</i>	
	Management of refractory skin lupus	<i>Annegret Kuhn (Germany), Marzia Caproni (Italy)</i>
	<i>Moderator/Facilitator: Bernardo Pons-Estel (Argentina)</i>	
	Management of cardiovascular risk in SLE	<i>Murray Urowitz (Canada), Eloisa Bonfá (Brazil)</i>

## Programme

	<i>Moderator/Facilitator: Sandra Navarra (Philippines)</i>	
	Fertility and pregnancy issues in patients with lupus nephritis	<i>Angela Tincani (Italy), Liz Lightstone (UK)</i>
	<i>Moderator/Facilitator: David Isenberg (UK)</i>	
	Rare disease manifestations in SLE	<i>Zahir Amoura (France), Richard Furie (USA)</i>

### FOUR HOT TOPICS (SESSION 2)

CET (UTC+2 Paris, Amsterdam, Berlin) 17:30 – 19:40 hours

EDT (UTC-4 New York, Montreal, Lima) 11:30 AM – 1:40 PM

CST (UTC+8 Beijing, Manila, Perth) 23:30 – 01:40 hours

	<i>Moderator: Thomas Dörner (Germany)</i>	
	Remission and low disease activity: the new targets for treatment	<i>George Bertias (Greece)</i>
	Belimumab helps lupus patients to achieve lupus targets	<i>Andrea Doria (Italy)</i>
	Can we withdraw low-dose prednisone in remitted patients?	<i>Zahir Amoura (France)</i>
	Can we withdraw immunosuppressants in remitted patients?	<i>Margherita Zen (Italy)</i>
	<i>Panel Discussion and Q&amp;A</i>	<i>All</i>

### SUNDAY 13TH SEPTEMBER 2020

#### PRE-RECORDED SESSION\*

CET (UTC+2 Paris, Amsterdam, Berlin) 07:00 – 10:50 hours

EDT (UTC+4 New York, Montreal, Lima) 1:00 AM – 4:50 AM

CST (UTC+8 Beijing, Manila, Perth) 13:00 – 16:50 hours

	Keynote	
	<i>Moderator: Andrea Doria (Italy)</i>	
	Understanding and treating SLE: A new era is dawning <i>Recorded Q&amp;A (15 Mins)</i>	<i>Ronald van Vollenhoven (Netherlands)</i>
<b>Debate: New Developments in Basic Science and Clinical Research: Defining SLE</b>		
	<i>Moderator: Ricard Cervera (Spain)</i>	
	The matter of the debate	<i>Ricard Cervera (Spain)</i>
	A majority of lupus patients (will) need a biologic!	<i>David Isenberg (UK)</i>
	A minority of lupus patients (will) need a biologic!	<i>Murray Urowitz (Canada)</i>
	<i>Recorded Voting, Q&amp;A and Discussion (20 Mins)</i>	<i>All</i>
<b>Hot Topic</b>		
	<i>Moderators: Murray Urowitz (Canada), David Isenberg (UK)</i>	
	Optimal assessment and monitoring of SLE patients in clinical practice <i>Recorded Q&amp;A (10 Mins)</i>	<i>Alexandre Voskuyl (Netherlands)</i>
<b>State-of-the-art</b>		
	<i>Moderators: Bevra Hahn (USA), Sandra Navarra (Philippines)</i>	
	Diagnosis and treatment of neuropsychiatric lupus <i>Q&amp;A (10 Mins)</i>	<i>Marcello Govoni (Italy)</i>
	Covid-19 and SLE – What do we know today? <i>Q&amp;A (10 Mins)</i>	<i>Fabrizio Conti (Italy)</i>

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

**MEET THE EDITOR**

CET (UTC+2 Paris, Amsterdam, Berlin) 11:00 – 11:55 hours

EDT (UTC+4 New York, Montreal, Lima) 5:00 AM – 5:55 AM

CST (UTC+8 Beijing, Manila, Perth) 17:00 – 17:55 hours

	<i>Moderator: Ronald van Vollenhoven (Netherlands)</i>	
	Introduction: What is happening in the world of publishing?	<i>Ronald van Vollenhoven (Netherlands)</i>
	Workshop: How do I get my manuscript published—in the best possible journal?	
	Tips for reviewers: make it work for the authors and yourself	

**POSTER SESSION**

CET (UTC+2 Paris, Amsterdam, Berlin) 12:00 – 12:50 hours

EDT (UTC+4 New York, Montreal, Lima) 6:00 AM – 6:50 AM

CST (UTC+8 Beijing, Manila, Perth) 18:00 – 18:50 hours

<b>Poster</b>		
	<i>Moderators: Ronald van Vollenhoven (Netherlands)/Andrea Doria (Italy)</i>	
	Posters: Lupus Academy Commendation Five Posters Presentations*: (5 minutes each) Q&A (5 minutes each poster)	

\*More Posters Available Online

**ROUNDTABLE: REFRACTORY LUPUS MANIFESTATIONS: DEFINITION AND TREATMENT**

CET (UTC+2)Paris, Amsterdam, Berlin) 13:00 – 15:00 hours

EDT (UTC+4)New York, Montreal, Lima) 7:00 AM – 9:00 AM

CST (UTC+8 Beijing, Manila, Perth) 19:00 – 21:00 hours

	<i>Moderators: Andrea Doria (Italy), Ronald van Vollenhoven (Netherlands)</i>	
	Refractory lupus nephritis Q&A (10 Mins)	<i>Sandra Navarra (Philippines)</i>
	Refractory lupus cytopenias Q&A (10 Mins)	<i>Eloisa Bonfá (Brazil)</i>
	Refractory musculoskeletal manifestations Q&A (10 Mins)	<i>Bernardo Pons-Estel (Argentina)</i>
	Refractory and/or catastrophic APS in SLE Q&A (10 Mins)	<i>Ricard Cervera (Spain)</i>
	Panel Discussion and Q&A	<i>All</i>
	Close	<i>Andrea Doria (Italy) Ronald van Vollenhoven (Netherlands)</i>